Search

Wolfgang Glaesner

from San Diego, CA
Age ~59
Get Report
Also known as:
Wolfganag Glaesner, Gregory A Moser, Lindsay Picker
Phone and address:
4457 Calle Mar De Armonia, San Diego, CA 92130
(858) 794-4063
Related to:
Cheryl KickerAnja Koester, 57
Connected to:
Marsha Glaesner, 68Emily C Glaessner, 32Aaron G Glafenhein, 36Angela N Glagavs, 53Alcinda A Glagola, 90Caroline J Glagola, 38Stephen L Glagola, 61Marina S Glagolev, 66Rose Glagow, 74Jeanne E Glahn, 67

Wolfgang Glaesner Phones & Addresses

  • 4457 Calle Mar De Armonia, San Diego, CA 92130 (858) 794-4063
  • Seattle, WA
  • Ramona, CA
  • San Marcos, CA
  • Carmel, IN
  • Indianapolis, IN
  • 4457 Calle Mar De Armonia, San Diego, CA 92130

Work

Company: Eli lilly and company Jan 2009 Position: Cso-biotechnology discovery research san diego

Education

Specialities: Biochemistry

Skills

Biotechnology • Adme • Drug Discovery • In Vitro • Medicinal Chemistry • Life Sciences • Translational Medicine • Immunology • In Vivo • Drug Metabolism • Drug Development • Lc Ms • Clinical Trials • Ind • Toxicology • Molecular Biology • Pharmacokinetics • Cell • Biochemistry • Pharmaceutical Industry • Protein Chemistry • Chromatography • Hplc • Cancer Research • Clinical Development • Protein Engineering • Lifesciences • Cell Biology • Cancer • Drug Delivery • Neuroscience • Cro • Cell Culture • Glp • Pharmacodynamics • Oncology • Signal Transduction • Bioanalysis • Technology Transfer • Organic Synthesis • Genomics • Vaccines • Diabetes • Assay Development

Industries

Pharmaceuticals

Resumes

Resumes

Wolfgang Glaesner Photo 1

Cso-Biotechnology Discovery Research San Diego

View page
Location:
4457 Calle Mar De Armonia, San Diego, CA 92130
Industry:
Pharmaceuticals
Work:
Eli Lilly and Company
Cso-Biotechnology Discovery Research San Diego
Education:
The University of Göttingen 1992 - 1995
Doctorates, Doctor of Philosophy, Biochemistry
Skills:
Biotechnology
Adme
Drug Discovery
In Vitro
Medicinal Chemistry
Life Sciences
Translational Medicine
Immunology
In Vivo
Drug Metabolism
Drug Development
Lc Ms
Clinical Trials
Ind
Toxicology
Molecular Biology
Pharmacokinetics
Cell
Biochemistry
Pharmaceutical Industry
Protein Chemistry
Chromatography
Hplc
Cancer Research
Clinical Development
Protein Engineering
Lifesciences
Cell Biology
Cancer
Drug Delivery
Neuroscience
Cro
Cell Culture
Glp
Pharmacodynamics
Oncology
Signal Transduction
Bioanalysis
Technology Transfer
Organic Synthesis
Genomics
Vaccines
Diabetes
Assay Development

Publications

Us Patents

Glucagon-Like Peptide-1 Analogs

View page
US Patent:
7101843, Sep 5, 2006
Filed:
Aug 14, 2002
Appl. No.:
10/485619
Inventors:
Wolfgang Glaesner - Indianapolis IN, US
Rohn Lee Millican - Indianapolis IN, US
Lianshan Zhang - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianaoplis IN
International Classification:
A61K 38/26
C07K 14/605
US Classification:
514 2, 514 12, 530308, 530324
Abstract:
Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.

Amidated Glucagon-Like Peptide-1

View page
US Patent:
7199217, Apr 3, 2007
Filed:
Nov 30, 2001
Appl. No.:
10/450042
Inventors:
Richard Dennis DiMarchi - Carmel IN, US
Wolfgang Glaesner - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 14/605
US Classification:
530324, 530308, 514 12
Abstract:
The present invention encompasses a GLP- analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.

Glp-1 Fusion Proteins

View page
US Patent:
7271149, Sep 18, 2007
Filed:
Nov 29, 2001
Appl. No.:
10/433108
Inventors:
Wolfgang Glaesner - Indianapolis IN, US
Radmila Micanovic - Indianapolis IN, US
Sheng-Hung Rainbow Tschang - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/26
C07K 14/605
C07K 14/76
US Classification:
514 12, 530308, 530362
Abstract:
The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.

Glp-1 Analog Fusion Proteins

View page
US Patent:
7452966, Nov 18, 2008
Filed:
Jun 10, 2004
Appl. No.:
10/558627
Inventors:
Wolfgang Glaesner - Indianapolis IN, US
Andrew Mark Vick - Fishers IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/26
C07K 14/605
US Classification:
530324, 514 12, 530308
Abstract:
The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.

Extended Glucagon-Like Peptide-1 Analogs

View page
US Patent:
7482321, Jan 27, 2009
Filed:
Jan 3, 2003
Appl. No.:
10/499111
Inventors:
Wolfgang Glaesner - Indianapolis IN, US
Wayne David Kohn - Indianapolis IN, US
Rohn Lee Millican - Indianapolis IN, US
Lianshan Zhang - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/26
C07K 14/605
US Classification:
514 12, 530308
Abstract:
The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.

Muteins Of Fibroblast Growth Factor 21

View page
US Patent:
7491697, Feb 17, 2009
Filed:
Dec 1, 2004
Appl. No.:
10/579510
Inventors:
John Michael Beals - Indianapolis IN, US
Christopher Carl Frye - Bargersville IN, US
Wolfgang Glaesner - Indianapolis IN, US
Shun Li - Carmel IN, US
Radhakrishnan Rathnachalam - Carmel IN, US
Jing Shang - Fishers IN, US
Beth Ann Strifler - Brownsburg IN, US
Radmila Micanovic - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 14/50
A61K 38/18
US Classification:
514 12, 514 2, 530399
Abstract:
The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Method Of Treating A Subject Suffering Stroke Comprising Administering Glucagon-Like Peptide-1 Analogs

View page
US Patent:
7498308, Mar 3, 2009
Filed:
May 18, 2006
Appl. No.:
11/436457
Inventors:
Wolfgang Glaesner - Indianapolis IN, US
Rohn Lee Millican - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/00
C07K 38/00
US Classification:
514 12, 530324
Abstract:
Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.

Polyethylene Glycol Linked Glp-1 Compounds

View page
US Patent:
7557183, Jul 7, 2009
Filed:
Mar 19, 2004
Appl. No.:
10/548328
Inventors:
Richard Dennis DiMarchi - Carmel IN, US
Wolfgang Glaesner - Indianapolis IN, US
Andrew Mark Vick - Fishers IN, US
Lianshan Zhang - Carmel IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/26
A61K 38/00
US Classification:
530308, 530324, 514 12
Abstract:
The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
Control profile
Wolfgang Glaesner from San Diego, CA, age ~59 Get Report